HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee Backs Japan’s 1st SGLT-2 Inhibitor
December 2, 2013
- 11 APIs/33 Products Including ComPlavin Added to NHI Price List
December 2, 2013
- PFSB Issues Notification Calling for Revisions of Package Inserts for Drugs Including Aricept, Cravit
December 2, 2013
- Toned-Down Proposal on “Precursor” Premium Still Leaves CSIMC Wary; 10% Tabled with Strings Attached
November 29, 2013
- New Proposals by Regulatory Reform Council Include Elimination of 14-Day Prescription Limit
November 29, 2013
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
- RMPs Required for Generics when RMPs Submitted for Original Products: Health Ministry
November 27, 2013
- Nearly 60% of Face-to-Face Consultations from July 2011 through September 2013 Involved Drugs: PMDA
November 26, 2013
- Subcommittee Agrees to Introduction of New Price Reduction Rule for Long-Listed Drugs Next Year; Will Continue to Discuss Details
November 22, 2013
- JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
- Upper House Passes Amended Pharmaceutical Affairs Law and Law to Ensure Safety of Regenerative Medicine
November 21, 2013
- Decision on Long-Term Prescriptions to Be Based on Results of Discussions at CSIMC: Government
November 21, 2013
- Plan Floated to Merge NIBIO Unit, JST to Create Japan-Version NIH: Govt Source
November 20, 2013
- Finance Minister Pushes Drastic Price Cuts for Off-Patent Drugs with Low Generic Penetration
November 20, 2013
- Administrative Reform Council Calls for Further Promotion of Generics, Elimination of OTC-like Drugs from Insurance Coverage
November 20, 2013
- PAFSC’s Second Committee Supports Approval of NBI’s Lung Cancer Drug, Takeda’s Malignant Lymphoma Treatment
November 19, 2013
- PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…